Insider selling is a good thing when insiders are taking profits in stocks with increasingly bullish outlooks. In this case, one stock is a solid, cash-producing dividend growth machine, while the other is a commercial-stage biopharma with an outlook for double-digit, verging on hyper-growth. In both cases, these stocks are pulling back from early 2026 highs, driven by insider selling, and opening entry points for new investors.
